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Two Pseudomonas aeruginosa strains resistant to beta-lactams, fluoroquinolones, aminoglycosides, tetracy-
clines, and carbapenems and susceptible only to polymyxin B (MIC < 2 g/ml) were identified as part of the
Meropenem Yearly Susceptibility Test Information Collection program. Metallo--lactamase screening tests
were positive, PCR yielded products with blaVIM primers, and sequence analysis revealed blaVIM-7 and blaVIM-2.
The isolates had distinct ribotype and pulsed-field gel electorphoresis patterns and appeared independently,
remote in time and location, at the same cancer center.
Carbapenems are among the best choices for the treatment
of infections caused by gram-negative bacilli. However, car-
bapenem resistance due to various mechanisms is being re-
ported. Modifications in outer membrane permeability result
in imipenem resistance, with low-grade meropenem resistance.
Up-regulation of the efflux system likely affects meropenem
and ertapenem more than imipenem. Hyperproduction of
AmpC -lactamases with these two resistance mechanisms can
further reduce carbapenem potency (7). A fourth mechanism
is the production of carbapenemases which hydrolyze many
-lactam antibiotics, including carbapenems (6). These en-
zymes have been detected among nonfermentative gram-neg-
ative bacilli as well as the Enterobacteriaceae (12).
Pseudomonas aeruginosa is a leading cause of nosocomial
infections (9). It is a significant pathogen in cancer patients,
and identification of carbapenem-resistant strains is a concern.
The first metallo--lactamase producing P. aeruginosa strain in
the United States was reported from M. D. Anderson Cancer
Center (MDACC) (10, 11). Here we report the characteristics
and genetic relationships of two additional metallo--lacta-
mase producing P. aeruginosa strains from the same center
compared to the index strain.
A total of 196 P. aeruginosa isolates were referred to JMI
Laboratories (North Liberty, IA), from MDACC over a
7-year period (1999 to 2006) as part of the Meropenem
Yearly Susceptibility Test Information Collection longitudi-
nal surveillance program. Isolate identification was con-
firmed using standard biochemical tests and Vitek cards
(bioMe´rieux, Hazelwood, MO). Antimicrobial susceptibility
testing was performed using CLSI (formerly NCCLS)-de-
scribed microdilution methodology (2). Escherichia coli ATCC
25922, P. aeruginosa ATCC 27853, and Staphylococcus aureus
ATCC 29213 were used as quality control organisms for these
experiments. Interpretations of susceptibilities for all agents
tested were by CLSI criteria (2). Screening for metallo--
lactamase was performed by the disk approximation test using
a modification of the procedure described by Arakawa et al.
(1). Acinetobacter baumannii 54/97 (IMP-2 producer) was used
as a positive control. Metallo--lactamase E-test strips (AB
BIODISK, Solna, Sweden) were used to confirm the disk ap-
proximation test results. Isolates exhibiting a positive disk ap-
proximation test for metallo--lactamase were screened for
IMP- and VIM-like genes using primers spanning the con-
served sequences within the respective enzyme types. Metallo-
-lactamases and their genetic contexts were studied by se-
quencing the gene segment accomplished using 5 and 3
conserved sequence primers from the class 1 integron as pre-
viously described. Sequences obtained were analyzed using
NCBI BLAST search to determine the enzyme types.
Characteristics of the index case from 2001 have been previ-
ously described (10, 11). Two additional cases at the same insti-
tution (MDACC) occurred remote in time and location (July
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TABLE 1. Antimicrobial agent susceptibilities of
metallo--lactamase-producing P. aeruginosa
isolates from MDACC
Antimicrobial agent
MIC (g/ml) for isolate no. (yr):
7-406 (2001) 4623 (2003) 1-1852 (2004)
Imipenem 8 8 8
Meropenem 8 8 8
Piperacillin-tazobactam 64 64 64
Aztreonam 16 16 16
Cefepime 16 16 16
Amikacin 32 32 32
Ciprofloxacin 2 2 2
Polymyxin B 2 1 2
614
2003 and January 2004) from the index case and each other. The
P. aeruginosa strains isolated from these two cases were further
characterized in the present study. Strains from the index case
and case 3 (2004) were resistant to all -lactams as well as the
aminoglycosides and fluoroquinolones as summarized in Table 1.
The isolates were susceptible to polymyxin B. All three strains
exhibited positive disk approximation tests to one or more -lac-
tam substrates (imipenem, meropenem, or ceftazidime), and the
recorded responses of all three strains were phenotypically differ-
ent (Table 2). Generic blaVIM primers yielded PCR products in
both new cases. Sequencing results revealed blaVIM-7 in the first
position (5 end) of the integron amplified from strain 4623 (case
2), with the same genetic context as the index strain reported in
2001 (strain 7-406; case 1). blaOXA-45 was identified in the index
strain (not on the integron carrying blaVIM-7) but was not present
in strain 4623 (Table 2). Sequencing of the PCR amplicon ob-
tained from strain 1-1852 (case 3) revealed blaVIM-2, which has
many key amino acid variations compared to blaVIM-7, ruling out
the possibility of simple evolution from the blaVIM-7 gene pool
that had previously been identified at MDACC. The VIM-7-
producing strain in this study (strain 4623) and the index strain
(strain 7-406) showed different ribotypes as well as pulsed-field
gel electrophoresis patterns that were also distinct from the VIM-
2-producing strains (1-1852).
In the past few years there have been several reports of me-
tallo--lactamase-producing P. aeruginosa isolates from Europe,
Latin America, and Asia (3, 4, 5, 12). This mechanism of carbap-
enem resistance remains uncommon in North America, with only
a few published reports so far (11). Metallo--lactamases have a
broad spectrum of hydrolytic activity against amino-carboxyl- and
ureidopenicillins, cephalosporins, cephamycins, and carbapenems
but not monobactams (3). The VIM enzymes of this group are
usually carried on mobile gene cassettes inserted into the class 1
integron, located chromosomally on a resistant plasmid. The VIM
type of enzymes (VIM-1 to -11) were initially described for P.
aeruginosa and Acinetobacter spp. and subsequently for Serratia
marcescens, Pseudomonas putida, Pseudomonas stutzeri, Klebsiella
pneumoniae, andE. coli, predominantly in Asia and Europe (3, 8).
Analysis of molecular and epidemiological characterization com-
bined with patient demographics leads to the following assump-
tions regarding the emergence of these VIM-type metallo--
lactamases at MDACC. (i) The VIM-7-producing index case
appears to have arisen independently in the United States, pos-
sibly under pressure of carbapenem usage rather than by dissem-
ination from Europe or Asia. (ii) blaVIM-7 reemerged 2 years later
in a clonally unrelated strain. Considering that the integron se-
quences of the strains isolated in this case and in the index case
were identical, a horizontal transfer of the entire blaVIM-7-con-
taining integron probably occurred. (iii) The VIM-2-producing
strain was isolated from a patient who may have been treated with
carbapenems in Jordan. Although the carbapenemase gene pool
in Jordan is not well known, blaVIM-2 may be present, as it is
widespread in Eastern Europe and Asia (4). However, blaVIM-2
could also have been acquired in the United States. Although
metallo--lactamases generally do not hydrolyze aztreonam, all 3
strains were nonsusceptible to the monobactam, suggesting an-
other mechanism of resistance (11).
Metallo--lactamase-producing strains pose a serious threat
to patients, mandating careful antibiotic stewardship and in-
fection control programs. Additionally, the need for routine
diagnostic smears for these enzymes (1, 4, 7) and the develop-
ment of novel antimicrobial agents highly active against organ-
isms producing these enzymes is paramount.
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TABLE 2. Summary of molecular epidemiologic investigations of metallo--lactamase-producing P. aeruginosa isolated from MDACC
Isolate
no. Yr
Disk approximation test result witha: VIM
PCR
result
Ribotype/PFGEb
pattern Carbapenemase(s)IMI 
EDTA
MEM 
EDTA
IMI 
2-MPA
MEM 
2-MPA
CAZ 
EDTA
7-406 2001       105.528.6/A VIM-7, OXA-45
4623 2003       258.151.2/B VIM-7
1-1852 2004       258.231.1/C VIM-2
a Various substrate-inhibitor combination interactions described. IMI, imipenem; MEM, meropenem; CAZ, ceftazidime; 2-MPA, 2-mercaptopropionic acid.
b PFGE, pulse-field gel electrophoresis.
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